Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in CTNM held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 2.8M | $46.6M | 0.0% | 7.600% | 0.85% |
| 2 | Jupiter Topco LLC | 2.7M | $44.8M | β | 7.315% | 0.02% |
| 3 | BlackRock, Inc. | 2.1M | $33.8M | +208.5% | 5.522% | 0.00% |
| 4 | JOHNSON & JOHNSON | 2.0M | $32.4M | 0.0% | 5.294% | 4.06% |
| 5 | FRANKLIN TEMPLETON INC | 1.8M | $30.1M | 0.0% | 4.920% | 0.01% |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 1.5M | $25.0M | -9.7% | 4.073% | 0.03% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $21.7M | +8.8% | 3.534% | 0.00% |
| 8 | PERCEPTIVE ADVISORS LLC | 1.3M | $20.6M | 0.0% | 3.358% | 0.31% |
| 9 | FMR LLC | 1.0M | $17.0M | +27.6% | 2.782% | 0.00% |
| 10 | MILLENNIUM MANAGEMENT LLC | 932K | $15.3M | -39.3% | 2.492% | 0.01% |
| 11 | GREAT POINT PARTNERS LLC | 921K | $15.1M | +15.2% | 2.465% | 2.85% |
| 12 | Longaeva Partners L.P. | 813K | $13.3M | +11.0% | 2.174% | 0.29% |
| 13 | Ikarian Capital, LLC | 808K | $13.2M | 0.0% | 2.161% | 1.43% |
| 14 | SECTORAL ASSET MANAGEMENT INC | 728K | $11.9M | 0.0% | 1.946% | 8.32% |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 693K | $11.4M | +145.8% | 1.854% | 0.00% |
| 16 | HHLR ADVISORS, LTD. | 669K | $11.0M | 0.0% | 1.790% | 1.32% |
| 17 | Red Tree Management, LLC | 638K | $10.5M | 0.0% | 1.707% | 7.10% |
| 18 | Versant Venture Management, LLC | 543K | $8.9M | 0.0% | 1.451% | 5.47% |
| 19 | GOLDMAN SACHS GROUP INC | 497K | $8.2M | +61.9% | 1.330% | 0.00% |
| 20 | Boxer Capital Management, LLC | 494K | $8.1M | 0.0% | 1.321% | 0.61% |
| 21 | STATE STREET CORP | 426K | $7.0M | +320.5% | 1.139% | 0.00% |
| 22 | CITADEL ADVISORS LLC | 396K | $6.5M | +13.2% | 1.060% | 0.00% |
| 23 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 328K | $5.4M | β | 0.877% | 0.01% |
| 24 | SILVERARC CAPITAL MANAGEMENT, LLC | 296K | $4.9M | -1.8% | 0.792% | 0.50% |
| 25 | ADAR1 Capital Management, LLC | 279K | $4.6M | +0.8% | 0.746% | 0.21% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in CTNM β a direct measure of their conviction.
Filings activity in CTNM during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new CTNM position in Q2 2026
Institutions that fully closed their CTNM position in Q2 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +13% | 81.74% | 0.30 pp | $500M | +26% |
| Q1 2026 | 90 | +14% | 82.04% | 14.07 pp | $398M | +18% |
| Q4 2025 | 79 | +32% | 96.11% | +33.74 pp | $337M | +64% |
| Q3 2025 | 60 | 15% | 62.37% | +8.75 pp | $205M | +272% |
| Q2 2025 | 71 | +11% | 53.62% | 4.97 pp | $55M | 48% |
| Q1 2025 | 64 | +3.2% | 58.59% | 2.59 pp | $105M | 54% |
| Q4 2024 | 62 | +19% | 61.18% | +8.23 pp | $231M | 9.8% |
| Q3 2024 | 52 | β | 52.95% | β | $256M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying CTNM stock.
Based on Q2 2026 13F filings, institutional ownership of Contineum Therapeutics, Inc. stands at 81.7%, held across 102 reporting institutions.
MONTANOVA CAPITAL, LLC is the largest reported institutional holder of CTNM, with approximately 2,841,334 shares worth $0.05B as of Q2 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of CTNM, including MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for CTNM is 55 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
28 institutions opened new positions in CTNM during Q2 2026, while 14 fully exited. 62 added to existing positions and 11 trimmed.
CTNM institutional ownership fell by 0.30 percentage points quarter-over-quarter, with a net change of +12 holders.
The top 10 institutions account for 57.4% of all reported 13F value in CTNM, and the top 25 account for 85.4%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.